From approximately 1980, the field of medical diagnostics was transformed by the wider adoption of positron emission tomography (PET). Unlike traditional imaging techniques that primarily focused on capturing static anatomical structures, PET scans provided clinicians with the ability to visualise patterns of biological and metabolic activity within the body. By detecting the emissions from radioactive tracers introduced into the patient, this technology offered a dynamic view of how organs and tissues were functioning at a cellular level.

The clinical utility of PET imaging became particularly significant across several specialised medical disciplines, where understanding physiological processes was as critical as identifying physical abnormalities. Its application proved essential in the following areas:

• Oncology, for the detection and monitoring of malignant tumours.
• Neurology, for mapping brain function and diagnosing neurodegenerative conditions.
• Cardiology, for assessing myocardial blood flow and heart tissue viability.

The true potential of this diagnostic tool was further realised as it began to be integrated with other imaging modalities. By combining PET with computed tomography (CT) or magnetic resonance imaging (MRI), medical professionals could effectively overlay functional data onto high-resolution anatomical maps. This fusion of technologies allowed for the precise localisation of metabolic irregularities, significantly improving the accuracy of diagnoses and the planning of targeted treatments for patients worldwide.